COMMUNIQUÉS West-GlobeNewswire

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

13/09/2024 - 13:00

CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare [...]

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

13/09/2024 - 13:00

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin [...]

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

13/09/2024 - 13:00

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for [...]

XORTX Announces Results of Annual and Special Meeting of Shareholders

13/09/2024 - 13:00

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

13/09/2024 - 12:50

PRINCETON, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution [...]

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

13/09/2024 - 12:45

GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the previously disclosed [...]

The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share

13/09/2024 - 12:00

SAN JUAN CAPISTRANO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

13/09/2024 - 11:57

First mpox vaccine to obtain prequalification by the WHO Approval will help accelerate access to the vaccine for all African countries COPENHAGEN, Denmark, September 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) today [...]

Avance Clinical Joins the Australian Clinical Trials Roadshow, Sharing Cost and Time Benefits for Early-Phase US Biotechs

13/09/2024 - 11:23

WAKE FOREST, N.C. and ADELAIDE, Australia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the market-leading CRO for biotechs, announced today that Avance Clinical will represent the CRO sector at the Australian [...]

Notification of managers’ transactions

13/09/2024 - 09:36

ANNOUNCEMENT NO. 274 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S [...]

Cytovation to present full safety and efficacy data from the CICILIA Phase I/IIa trial evaluating CY-101 in solid tumors at ESMO 2024

13/09/2024 - 09:00

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of Adrenocortical Carcinoma, a [...]

Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO

13/09/2024 - 08:30

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug Development [...]

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

13/09/2024 - 08:30

Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces the successful pricing of its Private Placement [...]

Valneva annonce le succès de son augmentation de capital et lève environ 60 millions d’euros

13/09/2024 - 08:30

Saint-Herblain (France), 13 septembre 2024 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce aujourd’hui le succès de son Augmentation de [...]

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

13/09/2024 - 07:00

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq 1,2 New subcutaneous (SC) option reduces [...]

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

13/09/2024 - 04:37

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization [...]

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

13/09/2024 - 04:34

BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for [...]

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

13/09/2024 - 03:15

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]

MBX Biosciences Announces Pricing of Initial Public Offering

13/09/2024 - 01:11

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide [...]